{"task_id": "b807fa78c9fcf269", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 203/464)", "text": " first 2 years (e.g. \u00054 positive\n192\nBreast Cancer\n\n--- Page 214 ---\nHORMONAL THERAPY OVERVIEW (CONT\u2019D)\nnodes, low ER or grade 3 disease). Potential benefits\nare as follows:\n\u0002\nRELATIVE RISK REDUCTION IN MORTALITY\n32% for all\nregimens\n\u0002\nRELATIVE RISK REDUCTION IN RECURRENCE\n40% for\ntamoxifen, 56% for aromatase inhibitor regimens\nAPPROACH\nIN\nTHE\nMETASTATIC\nSETTING\npatients with slowly progressive disease, no visceral\ninvolvement, and minimal symptoms may be best\nserved with a trial of endocrine therapy. For preme\nnopausal women, consider ovarian ablation + tamox\nifen ! aromatase inhibitor 1 ! aromatase inhibitor\n2 ! fulvestrant ! megestrol. For postmenopausal\nwomen, aromatase inhibitor 1 ! tamoxifen ! aro\nmatase inhibitor 2 ! fulvestrant ! megestrol. Time\nHORMONAL THERAPY OVERVIEW (CONT\u2019D)\nto progression is 8 months with tamoxifen and 10\nmonths with aromatase inhibitors\nADJUVANT CHEMOTHERAPY OVERVIEW\nWHO SHOULD GET ADJUVANT CHEMOTHERAPY:\nTHE ST. GALLEN GUIDELINE\n\u0002\nLOW RISK\nnode negative and age \u000535, tumor\n\u00042 cm, grade 1, no lymphatic/vascular invasion,\nHer2/neu negative\n\u0002\nINTERMEDIATE RISK\nnode negative and at least one\nof age <35, tumor >2 cm, grade 2 3, lymphatic/\nvascular invasion, Her2/neu positive, or node posi\ntive (1 3 nodes) and Her2/neu negative\n\u0002\nHIGH RISK\nnode positive (1 3 nodes) and Her2/\nneu positive, node positive (4 or more nodes)\nAPPROACH TO SYSTEMIC THERAPY FOR BREAST CANCER\nER/PR +ve\nER/PR unknown\nER/PR ve\nLow risk\nH or nil\nH or nil\nN/A\nIntermediate risk\nH or Cx!H\nCx!H\nCx\nHigh risk\nCx!H\nCx!H\nCx\nwhere Cx=chemo, H=hormonal therapy\nWHO SHOULD GET ADJUVANT CHEMOTHERAPY:\nTHE NCCN GUIDELINE\n\u0002\nALL HISTOLOGIC SUBTYPES EXCEPT TUBULAR OR COLLOID\nCANCERS\nadjuvant chemotherapy should be given\nif \u00051 cm or node positive. Consider chemotherapy\nif 0.6 1 cm and high grade or lymphovascular inva\nsion. Add trastuzumab if Her2/neu positive\n\u0002\nTUBULAR\nOR\nCOLLOID\nCANCERS\nadjuvant che\nmotherapy should be given if \u00053 cm or node\npositive. Consider chemotherapy if 1 2.9 cm\nADJUVANT REGIMENS\n\u0002\nFIRST GENERATION\nCMF PO, AC\u00034, FEC50\u00036\n\u0002\nSECOND\nGENERATION\nCAF\u00036,\nFAC\u00036,\nCEF\u00036,\nFEC100\u00036, AC\u00034+D\u00034, DC\u00034\n\u0002\nTHIRD\nGENERATION\nDAC\u00036,\nFEC100\u00033+D\u00033,\nAC\u00034+T\u00034 (dose dense), FEC\u00034+T\u00038\n\u0002\nNOTE\nA=doxorubicin,\nC=cyclophosphamide,\nD=docetaxel,\nE=epirubicin,\nF=5 fluorouracil,\nM=methotrexate, T=paclitaxel\nESTIMATED BENEFITS OF ADJUVANT CHEMO\nTHERAPY\nRELATIVE RISK REDUCTION FOR MORTALITY\nPostmenopausal\nPremenopausal\n1st gen.\n8% ER+, 15% ER\n30%\n2nd gen.\n26% ER+, 32% ER\n44%\n3rd gen.\n40% ER+, 45% ER\n55%\nADJUVANT CHEMOTHERAPY OVERVIEW (CONT\u2019D)\nRELATIVE RISK REDUCTION FOR RECURRENCE\nPostmenopausal\nPremenopausal\n1st gen.\n12% ER+, 23% ER\n37%\n2nd gen.\n30% ER+, 38% ER\n50%\n3rd gen.\n43% ER+, 50% ER\n59%\nADVERSE EFFECTS OF ADJUVANT CHEMOTHERAPY\n\u0002\nALOPECIA\nanthracycline\nor\ntaxane\nregimens\n(100%), CMF (50%)\n\u0002\nFEBRILE NEUTROPENIA\nDAC (40%) and dose dense\nregimens require GCSF. CEF >FEC; FAC >FEC; ACT\n>AC/CMF\n\u0002\nNAUSEA AND VOMITING\nCMF >anthracyclines\n\u0002\nOTHER ACUTE SIDE EFFECTS\nfatigue and weight\ngain. With taxanes, may experience myalgia,\narthralgia, and neuropathy (motor, sensory)\n\u0002\nPREMATURE\nOVARIAN\nFAILURE\nCMF\n>CEF/FEC\n>AC; DAC >FAC\n\u0002\nOTHER\nLONG-TERM\nSIDE\nEFFECTS\ncardiotoxicity\n(dose dependent and increases with age, \b1%\nwith anthracycline doses used in adjuvant regi\nmens), secondary cancers (AML, MDS with alkylat\ning agents, \b1 2% depending on regimen)\nPREDICTIVE\nFACTORS\nFOR\nADJUVANT\nCHE\nMOTHERAPY BENEFIT\nyounger age, high grade,\nER negative, Her2 positive (possibly for anthracycline\nand taxane based regimens)\nAPPROACH IN THE ADJUVANT SETTING\nconsider\nfirst generation chemotherapy if risk of relapse\nADJUVANT CHEMOTHERAPY OVERVIEW (CONT\u2019D)\nBreast Cancer\n193", "text_length": 3675, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 203/464)", "type": "chunk", "chunk_index": 202, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.525038", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.525790", "status": "complete", "chunks_added": 2}